A Phase II Study Assessing Contrast-Enhanced MRI to Evaluate Response to Radiation Treatment for Prostate Cancer

Full Title

Evaluation of Treatment Response Using Multiparametric MRI after Prostate Radiotherapy

Purpose

The purpose of this study is to better understand prostate cancer changes after radiation treatment through the use of magnetic resonance imaging (MRI). MRI is an imaging test that can help identify prostate tumors. For patients with newly diagnosed prostate cancer, MRI may help doctors manage treatment better and sooner.

The MRI being assessed in this study uses a contrast agent called gadolinium, which is the standard contrast generally used in MRI testing. Researchers are assessing the use of contrast-enhanced MRI to better understand how a patient’s prostate cancer is responding to radiation treatment. Participants will have an initial MRI as well as follow-up scans. The results of this testing can help doctors tailor treatment more effectively for each patient.

Participants in this study will also have a prostate core biopsy six months into radiation treatment. The biopsy findings will enable doctors to learn how active a prostate tumor is at this time.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have nonmetastatic prostate cancer (disease which has not spread to other parts of the body) and be candidates for external beam radiation therapy.
  • Patients who have had the prostate surgically removed may not participate.
  • Patients must be able to undergo contrast-enhanced MRI and be willing to come to Memorial Sloan Kettering’s main campus in New York City for the initial MRI as well as follow-up MRI scans.
  • This study is for men age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Michael Zelefsky at 212-639-6802.

Protocol

14-172

Phase

II

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators